Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003673 · ClinicalTrials.gov registry record · Phase 2
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
A Phase 2 study of Leukemia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 10
- Study locations
NCT00003673: Completed Phase 2 study of Leukemia, sponsored by Pfizer.
NCT00003673 is a Phase 2 study of Leukemia that has completed, run by Pfizer. The registered enrollment target is 55 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003673, a Phase 2 study of Leukemia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
Conditions Studied
Interventions
- DRUG chemotherapy
- DRUG gemtuzumab ozogamicin
Study Locations (10)
New York
- Long Island Jewish Medical Center - New Hyde Park
- New York Presbyterian Hospital - Cornell Campus - New York
- State University of New York Health Sciences Center - Stony Brook - Stony Brook
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- University of Chicago Cancer Research Center - Chicago
Arizona
- Arizona Cancer Center - Tucson
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Massachusetts
- New England Medical Center Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Pennsylvania
- University of Pennsylvania Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 1998-03 |
| Est. Completion | 1999-03 |
| Phase | Phase 2 |
What the finished NCT00003673 record still lists
NCT00003673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which chemotherapy is the first listed.
NCT00003673 lists 10 locations in 7 states (New York, Illinois, Arizona).
Frequently Asked Questions
What is clinical trial NCT00003673 about?
NCT00003673 is a clinical study titled "CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3...
What is the current status of trial NCT00003673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 1998-03. Estimated completion is 1999-03.
What conditions does trial NCT00003673 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00003673?
The interventions under investigation include: chemotherapy (DRUG), gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00003673?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003673 being conducted?
This trial has 10 study locations across Arizona, California, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003673's enrollment target sits among peer trials
55 106th of 233 higher than 128 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia